Literature DB >> 6843134

Metastatic malignant melanoma of unknown primary origin: a study of 30 cases.

E Panagopoulos, D Murray.   

Abstract

Thirty patients with metastatic malignant melanoma of unknown primary origin treated at Emory University Clinic between 1940 and 1975 are presented. This group represents the 4.4% of all melanomas treated during the same period of time at Emory. Nineteen (63.3%) patients had nodal metastases only, and they were handled by radical lymphadenectomy of the involved area. The remaining 11 patients presented with lung or widespread subcutaneous metastatic disease and treated with biopsy and radiotherapy or chemotherapy. The former group experienced 28.6% five- and ten-year actuarial survival while patients with lung metastases succumbed within four months after diagnosis. Spontaneous regression of a typical melanoma skin lesion has been reported in three patients prior to development of metastatic disease.

Entities:  

Mesh:

Year:  1983        PMID: 6843134     DOI: 10.1002/jso.2930230104

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Metastases of malignant melanoma simulating soft tissue sarcoma. A clinico-pathological, light- and electron microscopic and immunohistochemical study of 21 cases.

Authors:  P Lodding; L G Kindblom; L Angervall
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Melanoma with unknown primary: report and analysis of 24 patients.

Authors:  Rita Clerico; Ugo Bottoni; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Valeria Devirgiliis; Stefano Calvieri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

Review 3.  Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.

Authors:  Kierstin Utter; Chloe Goldman; Sarah A Weiss; Richard L Shapiro; Russell S Berman; Melissa Ann Wilson; Anna C Pavlick; Iman Osman
Journal:  Oncology       Date:  2017-07-27       Impact factor: 2.935

4.  Utility of sentinel lymph node biopsy for solitary dermal melanomas.

Authors:  Yinin Hu; Puja Shah; George J Stukenborg; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2015-02-24       Impact factor: 3.454

5.  Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.

Authors:  Shamim Ejaz; Hassan Shawa; Samuel Alva Henderson; Mouhammed Amir Habra
Journal:  BMJ Case Rep       Date:  2013-06-19

6.  TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma.

Authors:  Qian-Jin Zhang; Robyn P Seipp; Susan S Chen; Timothy Z Vitalis; Xiao-Lin Li; Kyung-Bok Choi; Andrew Jeffries; Wilfred A Jefferies
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

7.  Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.

Authors:  Paolo Del Fiore; Marco Rastrelli; Luigi Dall'Olmo; Francesco Cavallin; Rocco Cappellesso; Antonella Vecchiato; Alessandra Buja; Romina Spina; Alessandro Parisi; Renzo Mazzarotto; Beatrice Ferrazzi; Andrea Grego; Alessio Rotondi; Clara Benna; Saveria Tropea; Francesco Russano; Angela Filoni; Franco Bassetto; Angelo Paolo Dei Tos; Mauro Alaibac; Carlo Riccardo Rossi; Jacopo Pigozzo; Vanna Chiarion Sileni; Simone Mocellin
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

8.  Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.

Authors:  Danielle Verver; Dirk J Grünhagen; Alexander C J van Akkooi; Maureen J B Aarts; Franchette W P J van den Berkmortel; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; Marye J Boers-Sonderen; John B A G Haanen; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Gerard Vreugdenhil; Cornelis Verhoef; Astrid A M van der Veldt
Journal:  Cancer Immunol Immunother       Date:  2021-03-27       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.